Abstract: The present invention relates to a method for the production of micro-particles of polysaccharides. The method includes preparing a feeding solution and a gelifying liquid to collect nebulized jets of the feeding solution. The feeding solution contains at least one polymer capable of forming micro-particle structures and at least one biologically active substance. The feeding solution is pressurized inside an air-less nebulizing unit and then nebulized through the unit itself so as to generate nebulized jets impacting the surface of the gelifying liquid.

Abstract: The present invention relates to a method for the production of micro-particles of polysaccharides. The method includes preparing a feeding solution and a gelifying liquid to collect nebulized jets of the feeding solution. The feeding solution contains at least one polymer capable of forming micro-particle structures and at least one biologically active substance. The feeding solution is pressurized inside an air-less nebulizing unit and then nebulized through the unit itself so as to generate nebulized jets impacting the surface of the gelifying liquid.

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NNO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NNO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: The present invention relates to microcapsules with a double-layer of natural polysaccharides—chitosan and alginate—gelified and stabilized by means of a divalent ion containing inside at least one biologically active substance. The microcapsules of the invention can be employed as carriers for the oral administration of biologically active substances, also associated with an adjuvant of the biological response of the same, administered for a preventive or therapeutic purpose. These substances can be chosen, for example, from antigens and adjuvants, suitable for immune response stimulation against infective and non-infective agents, or from chemotherapeutics and adjuvants with therapeutic type effects. According to the type of biologically active substance encapsulated in the microcapsules, there can be a variety of uses for oral vaccination or therapy in the human and veterinary field.

Abstract: New ruthenium dimeric complexes with high antimetastatic and antitumour activity and remarkable chemical stability are described.

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: A salt of an anionic complex of Ru(III) with an ammonium cation fof formula (I), where R1, R2 and R3, equal or different from each other, are selected from the group consisting of H, C1-C6 alkyl, linear or branched, saturated or unsaturated, C3-C7 cycloalkyl, phenyl and aryl; or NR1R2R3 is a 5-7-membered nitrogen-containing heterocycle, saturated or unsaturated, optionally containing one or more O, S and/or N atoms, said nitrogen atom being optionally substituted with a C1-C4 alkyl, aryl or benzyl residue; said nitrogen-containing heterocycle being optionally condensed with a benzo group and/or substituted with C1-C4 alkyl, C1-C4 alkoxyl, C1-C4 alkylthio, aryl or benzyl groups; where R4 and R5, equal or different from each other, are selected from the group consisting of H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl and aryl or R4 and R5 form, together with the S atom, a 4-7-membered heterocycle.

Abstract: The invention concerns a coordination complexes with R.sup.111 as central metal attached to a heterocyclic ligand in the apical position trans to a sulfoxide and their pharmaceutical compositions useful in antitumor therapy either alone or in combination with platinum complexes.

Abstract: 2-Adamantyl- and 1-adamantyl-D/L-glycyl-L-alanyl-D-isoglutamine and their derivatives of the formulae ##STR1## wherein R stands for a hydrogen atom or a MurNAc group, and hydrochlorides thereof, a process for the preparation thereof and their use to obtain pharmaceuticals, which are particularly indicated for the treatment of viral diseases and tumors and/or immunomodulations in humans and animals.

Abstract: 2-Adamantyl- and 1-adamantyl-D/L-glycyl-L-alanyl-D-isoglutamine and their derivatives of the formulae ##STR1## wherein R stands for a hydrogen atom or a MurNAc group, and hydrochlorides thereof,a process for the preparation thereof and their use to obtain pharmaceuticals, which are particularly indicated for the treatment of viral diseases and tumors and/or immunomodulations in humans and animals.